Adverse reactions, the role of regulatory agencies in the pharmacovigilance
The onset of unexpected adverse reaction and the measures to be taken to protect patients’ health have been very much debated lately. Laymen in this field are also starting to be familiar with the main regulatory agencies all over the world, from the European Medicine Agency (EMA) to its American counterpart, the Food and drug Administration (FDA), not to mention our Italian Medicines Agency (AIFA).
The current burning issue of COVID vaccines and the suspected adverse reactions occurred after the administration of one of them have put the accuracy and validity of these agencies’ work under the spotlight, triggering a battle of opinions with no holds barred, from conspiracy theories to political fiction.
However, concerned parties know very well how complex the control and monitoring processes are for the drugs on the market. And they also know very well that no report, no adverse reaction, no new evidence is neglected, and that reviews, suspensions and revocations of drug are measure that are regularly on th agenda of the regulatory agencies’ work in Europe and in the world.
It should not be forgotten, among other things, that pharmacovigilance – that is “the set of activities […] directed toward identifying, assessing, understanding and preventing adverse effects or any other problem related to the use of medicines, in order to ensure a favourable benefit/risk ratio for the population” – is the reason why regulatory agencies exist, as they were created just to have available a technical and scientific apparatus able to perform the controls required before and after the authorization and marketing of medicines. Much has happened after the “thalidomide case”: monitoring activities by the agencies can count on the availability of several tools allowing continuous updates, information exchange and data collection.
All concerned parties take part to the vigilance on medicines. The Italian National Pharmacovigilance Network (Rete Nazionale di Farmacovigilanza – RNF) involves primary care units, hospitals, care and research facilities, regions and provinces, as well as the very pharmaceutical companies holding medicinal products.
Inside the network, all pivotal figures in pharmaceutical management, from general practitioners to ER professionals, from hospital pharmacists to pharmacovigilance responsible persons, have the task of collect, manage and analyse the reports of suspected adverse reactions to drugs they become aware of. Even citizens, as patients, can contribute reporting suspected events to their doctor or to a hospital, taking care of reporting as many details as possible that can allow regulatory agencies and MA holders to either establish or exclude a cause (and not only a time) relation between the suspected adverse reaction and the received therapy.
This is just what is now happening with the Covid vaccine: AIFA has recorded the reports of adverse events time-related with the administration of the vaccine and is now assessing them in depth, in cooperation with the European national agencies and EMA, to establish as much accurately as possible if the vaccine may have been actually responsible of the deaths.
Therefore, through the pharmacovigilance activities, the AIFA and the regulatory agencies throughout the world, ensure that safety data about the drugs on the market are constantly updated, to protect public health and ensure prompt and effective interventions in all cases when this is believed to be at risk.
Written by: Maria Pia Felici
Foto di MasterTux da Pixabay
Previous Post
Next Post

